VOR - Vor Biopharma Inc.
IEX Last Trade
1.225
0.015 1.224%
Share volume: 26,883
Last Updated: Fri 27 Dec 2024 08:27:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.21
0.02
1.24%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-3.47%
1 Month
5.89%
3 Months
18.19%
6 Months
-26.49%
1 Year
-68.14%
2 Year
-86.68%
Key data
Stock price
$1.22
DAY RANGE
$0.92 - $1.27
52 WEEK RANGE
$0.68 - $2.64
52 WEEK CHANGE
-$62.76
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Bob Ang
Region: US
Website: vorbio.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vorbio.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Recent news